Netherlands· NL-6d511f686404
Selexipag Accord 400 microgram filmomhulde tabletten
A selexipag product containing selexipag, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Selexipag is registered in 13 of 19 countries.
Countries holding a registration under ATC B01AC27 (selexipag), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Selexipag · ATC B01AC27
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of selexipag costs, country by country.
Normalised to the WHO defined daily dose (1.8 mg), the median price runs from $809.99 in Switzerland to $1232.99 in Italy — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selexipag · price per daily dose (1.8 mg)
USD · FX 28 Sept 2026
- IT Italy$1232.99
- CH Switzerland$809.99
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SELEXIPAG
- Manufacturer
- Accord Healthcare B.V.
- Country
- Netherlands (NL)
- ATC code
- B01AC27
- ATC class
- Selexipag
- Defined daily dose
- 1.8 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id133586
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
237 interactions on record for selexipag.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selexipag · interactions on record
237 records
- 1 severe
- 232 moderate
- 4 minor
Most severe, free to view
- GemfibrozilC10AB04severe
- PapaverineA03AD01moderate
- MannitolA06AD16moderate
- GlycerolA06AX01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selexipag in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenSelexipag Accord 400 mikrogram Filmdragerad tablettAccord Healthcare B.V.
- CzechiaSELEXIPAG ACCORDACCORD HEALTHCARE POLSKA Sp. z o.o., Varšava
- PolandSelexipag AccordAccord Healthcare Polska Sp. z o.o.
- SpainSELEXIPAG ACCORD 400 MICROGRAMOS COMPRIMIDOS RECUBIERTOS CON PELICULA EFGAccord Healthcare S.L.U.
- IrelandSelexipag Accord 1 400 microgram film-coated tabletsAccord Healthcare Ireland Ltd.
- United StatesSelexipagZydus Pharmaceuticals (USA) Inc.
- NorwayUptraviJanssen-Cilag International N.V.
- FinlandUptraviJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 18 EEA countries. Names it is sold under:
- Austria · Selexipag Ratiopharm
- Cyprus · Selexipag Accord
- Denmark · Selexipag Accord, Selexipag Stada
- Estonia · Selexipag Stada
- Spain · Selexipag Accord, Selexipag Stada
- Greece · Xipeno
- Croatia · Seleksipag Accord
- Ireland · Selexipag Accord, Selexipag Clonmel
- Iceland · Selexipag Stada, Uptravi
- Italy · Selexipag Accord, Selexipag Eg
- Liechtenstein · Uptravi
- Lithuania · Selexipag Stada
- Latvia · Selexipag Stada
- Malta · Selexipag Clonmel
- Norway · Selexipag Accord, Selexipag Stada
- Poland · Selexipag, Selexipag Accord
- Portugal · Selexipag Accord, Selexipag Teva
- Sweden · Selexipag, Selexipag Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f3128a00-532b-4301-a3cf-d8325ef2bf10 GET /v1/drugs/f3128a00-532b-4301-a3cf-d8325ef2bf10?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h133586_smpc.pdf",
"strength": null,
"atc_label": "Selexipag",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133586",
"excipients": [
"CARNAUBAWAS (E 903)",
"COPOLYMEER VAN METHACRYLZUUR-METHYLMETHACRYLAAT (1:1)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ZWART (E 172)",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"MAÏSZETMEEL",
"PROPYLEENGLYCOL (E 1520)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"SELEXIPAG"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133586.pdf",
"authorised_at": "2025/10/16",
"procedure_number": "NL/H/6180/002",
"dispensing_status": "Uitsluitend recept",
"registration_number": "133586",
"additional_monitoring": "N"
}See everything about selexipag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.